Tempus AI Stock Falls After USC Deal, Putting Its Cancer Data Push To The Test
Tempus AI said Thursday it will deploy its molecular testing and AI tools across USC’s health system, covering more than 1.5 million annual patient visits. The agreement includes USC Norris Cancer Center and other affiliated hospitals. Tempus shares fell 7.3% to $51.44 on Nasdaq. The company reports Q1 results May 5.